| Literature DB >> 35976484 |
Dihui Cai1, Zequn Zheng1,2, Xiaojun Jin1, Yin Fu1, Lichao Cen1, Jiachun Ye1, Yongfei Song3, Jiangfang Lian4,5.
Abstract
Type 2 long QT syndrome (LQT2) is the second most common subtype of long QT syndrome and is caused by mutations in KCHN2 encoding the rapidly activating delayed rectifier potassium channel vital for ventricular repolarization. Sudden cardiac death is a sentinel event of LQT2. Preclinical diagnosis by genetic testing is potentially life-saving.Traditional LQT2 models cannot wholly recapitulate genetic and phenotypic features; therefore, there is a demand for a reliable experimental model. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) meet this challenge. This review introduces the advantages of the hiPSC-CM model over the traditional model and discusses how hiPSC-CM and gene editing are used to decipher mechanisms of LQT2, screen for cardiotoxicity, and identify therapeutic strategies, thus promoting the realization of precision medicine for LQT2 patients.Entities:
Keywords: Gene editing; Human-induced pluripotent stem cells; KCNH2; Precision medicine; Type 2 long QT syndrome
Year: 2022 PMID: 35976484 DOI: 10.1007/s12265-022-10298-x
Source DB: PubMed Journal: J Cardiovasc Transl Res ISSN: 1937-5387 Impact factor: 3.216